Company intelligence / Profile preview

StemVax Therapeutics

Chagrin Falls, Ohio, United States

Ownership: Private
Development stage: Other

Overview

Pre-clinical data shows enhanced immune response using patient-specific tumor antigens with TLR-AD1 adjuvants; FDA Orphan Drug Designation granted in 2022; IND filing planned.

Therapeutic areas: Oncology
Modalities: Dendritic cell vaccineVaccine
Industry: Biotech

Partnerships

Cedars-Sinai Medical Center

Beyond the preview

Go deeper on StemVax Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on StemVax Therapeutics.

Explore the full profile